The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
Aino Latva-RaskuMiikka-Juhani HonkaJoel KullbergNina MononenTerho LehtimäkiJuha SaltevoAnna K KirjavainenVirva SaunavaaraPatricia IozzoLars JohanssonJan OscarssonJarna Christina HannukainenPirjo NuutilaPublished in: Diabetes care (2019)
In this study, 8 weeks of treatment with dapagliflozin reduced liver PDFF and the volume of visceral adipose tissue in obese patients with type 2 diabetes. Although glycemic control was improved, no effect on tissue-level insulin sensitivity was observed.